Kinnate BioPharma downgraded by Stifel with a new price target
$KNTE
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel downgraded Kinnate BioPharma from Buy to Hold and set a new price target of $11.00 from $35.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/17/2022 | $35.00 → $11.00 | Buy → Hold | Stifel |
| 7/28/2022 | $33.00 | Buy | H.C. Wainwright |
| 9/27/2021 | $46.00 | Buy | Jefferies |
| 9/23/2021 | $32.00 | Buy | Stifel |
| 7/13/2021 | Outperform | William Blair |